Carcinogenesis Advance Access published online on October 4, 2007
Carcinogenesis, doi:10.1093/carcin/bgm219
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Survivin repression by p53, Rb, and E2F2 in normal human melanocytes
1 Department of Dermatology, University of Utah, 30 North 1900 East, Salt Lake City, Utah 84132, USA
2 Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA
3 Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA
4 Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
Correspondence: D Grossman, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA; Tel: (801) 581-4682; Fax: (801) 585-0900; E-mail: doug.grossman{at}hci.utah.edu
The inhibitor of apoptosis (IAP) protein Survivin is a dual mediator of apoptosis resistance and cell cycle progression, and is highly expressed in cancer. We have previously shown that Survivin is upregulated in melanoma compared to normal melanocytes, is required for melanoma cell viability, and that melanocyte expression of Survivin predisposes mice to UV-induced melanoma and metastasis. The mechanism(s) of Survivin upregulation in the course of melanocyte transformation, and its repression in normal melanocytes, however, has not been clearly defined. We show here that p53 and Rb, at basal levels and in the absence of any activating stimuli, are both required to repress survivin transcription in normal human melanocytes. Survivin repression in melanocytes does not involve alterations in protein stability or promoter methylation. p53 and Rb (via E2Fs) regulate Survivin expression by direct binding to the survivin promoter; p53 also affects Survivin expression by activating p21. We demonstrate a novel role for E2F2 in the negative regulation of Survivin expression. In addition, we identify a novel E2F-binding site in the survivin promoter and show that mutation of either the p53- or E2F-binding sites is sufficient to increase promoter activity. These studies suggest that compromise of either p53 or Rb pathways during melanocyte transformation leads to upregulation of Survivin expression in melanoma.
Key Words: Survivin • melanocyte • p53 • Rb • E2F
Received July 24, 2007; revised September 17, 2007; accepted September 23, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Conway, A. Mitra, R. Jewell, J. Randerson-Moor, S. Lobo, J. Nsengimana, S. Edward, D. S. Sanders, M. Cook, B. Powell, et al. Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival Clin. Cancer Res., November 15, 2009; 15(22): 6939 - 6946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu, S. C. Verma, M. Murakami, Q. Cai, P. Kumar, B. Xiao, and E. S. Robertson Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Upregulates Survivin Expression in KSHV-Associated B-Lymphoma Cells and Contributes to Their Proliferation J. Virol., July 15, 2009; 83(14): 7129 - 7141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas Cancer Res., May 1, 2008; 68(9): 3124 - 3132. [Abstract] [Full Text] [PDF]
|
|